# Splash Beverage Group, Inc. (NV) > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Splash Beverage Group, Inc. (NV)). ## Overview Endovia Health Sciences, Inc. is a U.S.-based company organized around cannabinoid health sciences, including pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and cannabinoid wellness products. The company also retains a legacy beverage distribution activity centered on Chispo tequila and operates through a public-company platform that can pursue acquisitions, licensing arrangements, and strategic partnerships. ## Products & services • Chispo tequila distribution • Cannabinoid wellness products • Human cannabinoid therapeutics • Veterinary cannabinoid therapeutics • Pharmaceutical asset commercialization • Strategic investments and licensing - **Cannabinoid wellness products** (30%) — Consumer-oriented cannabinoid products intended for wellness and related health applications. - **Pharmaceutical and therapeutic assets** (30%) — Human and veterinary cannabinoid therapeutics subject to development and regulatory requirements. - **Beverage distribution** (25%) — Legacy distribution of Chispo tequila through authorized U.S. and non-U.S. channels. - **Strategic investments and partnerships** (15%) — Acquisitions, licensing arrangements, partnerships, and investments supporting the health sciences platform. - Chispo tequila distribution - Cannabinoid wellness products - Human cannabinoid therapeutics - Veterinary cannabinoid therapeutics - Pharmaceutical asset commercialization - Strategic investments and licensing ## Customers The legacy beverage business sells Chispo tequila through distributors and directly or indirectly to Senor Frog locations, including establishments in Florida, The Bahamas, and Mexico. The planned health sciences platform is aimed at cannabinoid wellness consumers, healthcare and veterinary markets, and potential commercial partners seeking pharmaceutical or cannabinoid technologies. Distributors, retailers, brokers, licensees, and strategic acquisition partners are important because the company relies on external channels to commercialize products and expand market access. - **Senor Frog hospitality locations** (primary) — Purchase Chispo tequila for beverage service in restaurants and entertainment venues. - **Distributors, retailers, and brokers** (primary) — Handle placement, sales, and distribution of beverage and potential wellness products. - **Cannabinoid wellness consumers** (secondary) — Buy consumer wellness products for non-pharmaceutical health and lifestyle uses. - **Human and veterinary healthcare markets** (emerging) — Potential users and commercial channels for regulated cannabinoid therapeutics. - **Strategic partners and licensees** (secondary) — Provide technologies, products, capital, or market access for platform expansion. - Senor Frog locations purchase Chispo tequila for beverage service - Distributors and brokers provide market access and logistics - Retailers can carry branded beverage and wellness products - Wellness consumers may purchase cannabinoid products - Healthcare and veterinary markets may use regulated therapeutics ## Geography Endovia is incorporated in Nevada and its current operating footprint is centered on the United States. The legacy Chispo tequila activity has been associated with Senor Frog locations in Florida, The Bahamas, and Mexico, although the reports do not provide country-level revenue allocations. Future geographic exposure will depend on regulatory approvals, distribution relationships, and the ability to commercialize cannabinoid products across permitted markets. - Nevada corporation with a U.S.-centered operating platform - Chispo tequila is distributed in certain U.S. states - Florida Senor Frog locations are a reported beverage market - The Bahamas and Mexico are reported Chispo markets - Cannabinoid expansion depends on local regulatory frameworks ## Strategy The company is repositioning its public-company platform from legacy branded beverages toward cannabinoid health sciences. Priorities include commercializing pharmaceutical assets, developing FDA-regulated human and veterinary therapeutics, and pursuing cannabinoid wellness and beverage products through acquisitions, licensing, and partnerships. This strategy is intended to use the company’s public-market access and industry relationships to enter higher-growth regulated markets, but execution depends on completing transactions and obtaining required approvals. - **Establish the cannabinoid health sciences platform** (short-term) — The legacy beverage business has not generated sufficient scale to support the company. - **Commercialize pharmaceutical and therapeutic assets** (medium-term) — Regulated therapeutics could provide a more defensible platform than branded beverages. - **Expand through external transactions** (short-term) — Acquisitions, licensing, and partnerships can accelerate market entry and product access. - Build a diversified cannabinoid health sciences platform - Pursue pharmaceutical and therapeutic commercialization - Develop human and veterinary cannabinoid applications - Expand through acquisitions and licensing arrangements - Use partnerships to access products and technologies - Retain selective cannabinoid beverage opportunities ## Risks Endovia’s strategic transition creates execution risk because the company must replace a small legacy beverage operation with products and assets that may require regulatory approval, development capital, and new commercial capabilities. Its beverage model also depends on distributors, retailers, brokers, and individual customer orders, limiting control over demand and market access. Financing needs, transaction uncertainty, competition, and third-party dependence could materially affect the company’s ability to implement its strategy. - **Regulatory and commercialization risk** [critical] — Human and veterinary therapeutics may require clinical, regulatory, and compliance milestones before commercialization. - **Strategic transaction risk** [high] — Acquisitions, divestitures, and partnerships may not close or may distract management from operating activities. - **Distribution and demand volatility** [high] — Distributors are not required to place minimum orders and may prioritize competing products. - **Competitive pressure** [high] — Better-capitalized beverage and wellness companies can compete on pricing, marketing, and distribution. - **Third-party execution and compliance** [medium] — External service providers and business partners can create operational, legal, cybersecurity, and reputational exposure. - **Financing and liquidity risk** [critical] — The company has historically required external financing while operating cash generation remained limited. - Cannabinoid products may face lengthy regulatory approval requirements - Acquisitions and partnerships may fail or divert management attention - Distributors are not required to place minimum orders - Third-party partners may fail on delivery or compliance obligations - Larger beverage competitors can pressure pricing and shelf access - Limited operating scale increases financing and execution risk ## Accounting Revenue recognition requires judgment over transfer of control, customer returns, allowances, trade promotions, and distributor sell-through information, which can affect reported revenue timing and net sales. Accounts receivable allowances depend on customer creditworthiness and collection experience, while inventory is measured at the lower of cost or net realizable value and may require write-downs when demand weakens. Investments, acquisition-related assets, and other financial instruments may also require fair-value estimates that introduce valuation uncertainty. - **Revenue recognition** — Revenue and accounts receivable - **Allowance for doubtful accounts** — Accounts receivable and bad-debt expense - **Inventory valuation** — Inventory, cost of sales, and earnings - **Fair value measurements** — Assets, gains or losses, and equity - **Acquisition and investment accounting** — Goodwill, intangible assets, investments, and impairment expense - Revenue timing depends on control transfer and distributor terms - Returns and trade promotions can reduce reported net revenue - Distributor sell-through data affects revenue estimates - Bad-debt allowances reflect customer collectability judgments - Inventory write-downs may follow weak demand or obsolescence - Fair-value estimates can affect investments and financial assets --- *Last updated: 2026-09-24T11:16:11.250916+00:00*